Literature DB >> 18240184

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.

Vitaly Margulis1, Pheroze Tamboli, Surena F Matin, David A Swanson, Christopher G Wood.   

Abstract

BACKGROUND: To gain further insight into the natural history of papillary renal cell carcinoma (pRCC), the authors evaluated oncologic impact of important clinical and pathologic prognostic factors and performed survival analyses in a large group of contemporary patients surgically treated for pRCC.
METHODS: The institutional nephrectomy database was searched for patients who were managed with radical or partial nephrectomy for pRCC or clear cell RCC (cRCC) from 1994 to 2006.
RESULTS: A total of 2157 patients with pRCC (n=245) or cRCC (n=1912) met protocol inclusion criteria. Kaplan-Meier analyses revealed equivalent 5-year cancer-specific survival (CSS) in the nonmetastatic pRCC patient group and revealed significantly decreased CSS in pRCC patients with distant metastases compared with matched cRCC patient cohorts. Presence of venous tumor thrombus was associated with a significant decrease in CSS and was an independent prognostic feature in pRCC patient cohort but not in patients with cRCC (5-year CSS pRCC=35%; cRCC=66%; P= .012). Patients with pRCC were at a significantly increased risk of harboring metastatic lymph nodes compared with patients with cRCC (13% and 8.6%, respectively; P= .019); however, presence of lymph node metastases in patients with pRCC was associated with a relatively indolent disease course (5-year CSS pRCC=65%; cRCC=19%; P= .029).
CONCLUSIONS: The authors demonstrated significant differences in presentation, prognostic features, and patient outcomes among papillary and clear cell histologic subtypes of RCC. The authors' findings may potentially link unique molecular genetics that have been reported in pRCCs to its distinct clinical behavior.

Entities:  

Mesh:

Year:  2008        PMID: 18240184     DOI: 10.1002/cncr.23322

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Authors:  Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

Review 2.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

Authors:  E Jason Abel; Christopher G Wood
Journal:  Nat Rev Urol       Date:  2009-06-16       Impact factor: 14.432

Review 3.  Imaging features of solid renal masses.

Authors:  Massimo Galia; Domenico Albano; Alberto Bruno; Antonino Agrusa; Giorgio Romano; Giuseppe Di Buono; Francesco Agnello; Giuseppe Salvaggio; Ludovico La Grutta; Massimo Midiri; Roberto Lagalla
Journal:  Br J Radiol       Date:  2017-07-13       Impact factor: 3.039

Review 4.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 5.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

6.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

7.  [Gender-specific characteristics and survival of renal cell carcinoma].

Authors:  A J Schrader; S Sevinc; P J Olbert; A Hegele; Z Varga; R Hofmann
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

8.  Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.

Authors:  Sandra Steffens; Frederik C Roos; Martin Janssen; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Kerstin Junker; Markus A Kuczyk; Andres J Schrader
Journal:  Virchows Arch       Date:  2014-09-02       Impact factor: 4.064

9.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.

Authors:  Janice P Dutcher; Paul de Souza; David McDermott; Robert A Figlin; Anna Berkenblit; Alexandra Thiele; Mizue Krygowski; Andrew Strahs; Jay Feingold; Gary Hudes
Journal:  Med Oncol       Date:  2009-02-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.